| ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome AT Baker, RJ Boyd, D Sarkar, A Teijeira-Crespo, CK Chan, E Bates, ... Science advances 7 (49), eabl8213, 2021 | 126 | 2021 |
| Designer oncolytic adenovirus: coming of age AT Baker, C Aguirre-Hernández, G Halldén, AL Parker Cancers 10 (6), 201, 2018 | 92 | 2018 |
| Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor AT Baker, RM Mundy, JA Davies, PJ Rizkallah, AL Parker Science Advances 5 (9), eaax3567, 2019 | 71* | 2019 |
| Oncolytic virotherapy: Challenges and solutions NH Goradel, AT Baker, A Arashkia, N Ebrahimi, S Ghorghanlu, ... Current Problems in Cancer 45 (1), 100639, 2021 | 64 | 2021 |
| The fish pathogen Yersinia ruckeri produces holomycin and uses an RNA methyltransferase for self-resistance Z Qin, AT Baker, A Raab, S Huang, T Wang, Y Yu, M Jaspars, ... Journal of Biological Chemistry 288 (21), 14688-14697, 2013 | 53 | 2013 |
| Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions AT Baker, A Greenshields-Watson, L Coughlan, JA Davies, ... Nature communications 10 (1), 741, 2019 | 51 | 2019 |
| Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies H Uusi-Kerttula, JA Davies, JM Thompson, P Wongthida, L Evgin, ... Clinical Cancer Research 24 (17), 4215-4224, 2018 | 42 | 2018 |
| To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine‐induced thrombotic thrombocytopenia M Othman, AT Baker, E Gupalo, A Elsebaie, CM Bliss, MT Rondina, ... Journal of Thrombosis and Haemostasis 19 (11), 2845-2856, 2021 | 21 | 2021 |
| Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination A Buoninfante, A Andeweg, AT Baker, M Borad, N Crawford, JM Dogné, ... npj Vaccines 7 (1), 141, 2022 | 16 | 2022 |
| Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy PLS Uson Junior, U Majeed, J Yin, G Botrus, MB Sonbol, DH Ahn, ... JCO Precision Oncology 6 (1), e2100274, 2022 | 11* | 2022 |
| The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism AT Baker, JA Davies, EA Bates, E Moses, RM Mundy, G Marlow, DK Cole, ... Journal of Virology 95 (4), 10.1128/jvi. 01849-20, 2021 | 11 | 2021 |
| Exploring cryo-electron microscopy with molecular dynamics JW Vant, D Sarkar, J Nguyen, AT Baker, JV Vermaas, A Singharoy Biochemical Society Transactions 50 (1), 569-581, 2022 | 10 | 2022 |
| Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications SL Hulin-Curtis, JA Davies, D Nestić, EA Bates, AT Baker, TG Cunliffe, ... Cancer Gene Therapy 27 (10-11), 785-798, 2020 | 9 | 2020 |
| Oncolytic virus with attributes of vesicular stomatitis virus and measles virus in hepatobiliary and pancreatic cancers BM Nagalo, CA Breton, Y Zhou, M Arora, JM Bogenberger, O Barro, ... Molecular Therapy-Oncolytics 18, 546-555, 2020 | 9 | 2020 |
| Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers M Arora, JM Bogenberger, AM Abdelrahman, J Yonkus, R Alva‐Ruiz, ... Hepatology 75 (1), 43-58, 2022 | 6 | 2022 |
| In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications EA Bates, JR Counsell, S Alizert, AT Baker, N Suff, A Boyle, AC Bradshaw, ... Viruses 13 (8), 1483, 2021 | 6 | 2021 |
| FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations PLS Uson Junior, TT DeLeon, JM Bogenberger, RK Pai, HE Kosiorek, ... Digestive diseases and sciences, 1-9, 2022 | 5 | 2022 |
| Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10 EA Bates, JA Davies, J Váňová, D Nestić, VS Meniel, S Koushyar, ... Molecular Therapy-Oncolytics 25, 43-56, 2022 | 5 | 2022 |
| Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers BM Nagalo, Y Zhou, EJ Loeuillard, C Dumbauld, O Barro, NM Elliott, ... Hepatology, 2022 | 3 | 2022 |
| HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation VM Vlachava, S Seirafian, CA Fielding, S Kollnberger, RJ Aicheler, ... Proceedings of the National Academy of Sciences 120 (49), e2309077120, 2023 | | 2023 |
Alan L. ParkerProfessor of Translational Virotherapies, Cardiff UniversityVerified email at Cardiff.ac.uk
